Quidel to Hold Third Quarter 2017 Financial Results Conference Call on November 1, 2017
October 13 2017 - 4:30PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, will report third quarter 2017
financial results after market close on Wednesday, November 1,
2017.
Following the release of results, Douglas Bryant, president and
chief executive officer, and Randy Steward, chief financial
officer, will host an investment community conference call
beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to
discuss the results and answer questions. During the conference
call, the company will also discuss business and financial
developments and trends. The company's statements may contain or
constitute material information that has not been previously
disclosed.
To participate in the live call by telephone from the U.S., dial
877-930-5791, or from outside the U.S., dial 253-336-7286, and
enter the audience pass code 1067380.
A live webcast of the call can be accessed on the Investor
Relations section of the Quidel website (http://ir.quidel.com). The
website replay will be available for 14 days. The telephone replay
will be available for 48 hours beginning at 8:00 p.m. Eastern Time
(5:00 p.m. Pacific Time) on November 1, 2017 by dialing
855-859-2056 from the U.S., or by dialing 404-537-3406 for
international callers, and entering pass code 1067380.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being
of people around the globe through the development of diagnostic
solutions that can lead to improved patient outcomes and provide
economic benefits to the healthcare system. Marketed under the
Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and
InflammaDry® leading brand names, as well as under the new Solana®,
AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products
aid in the detection and diagnosis of many critical diseases and
conditions, including, among others, influenza, respiratory
syncytial virus, Strep A, herpes, pregnancy, thyroid disease and
fecal occult blood. Quidel's recently acquired Triage® system of
tests comprises a comprehensive test menu that provides rapid,
cost-effective treatment decisions at the point-of-care (POC),
offering a diverse immunoassay menu in a variety of tests to
provide you with diagnostic answers for quantitative BNP, CK-MB,
d-dimer, myoglobin, troponin I and qualitative TOX Drug Screen.
Quidel’s research and development engine is also developing a
continuum of diagnostic solutions from advanced immunoassay to
molecular diagnostic tests to further improve the quality of
healthcare in physicians’ offices and hospital and reference
laboratories. For more information about Quidel’s comprehensive
product portfolio, visit quidel.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171013005668/en/
Quidel CorporationRandy StewardChief Financial Officer(858)
552-7931orClermont PartnersAngie Mazza(312)
690-6006amazza@clermontpartners.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Aug 2024 to Sep 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Sep 2023 to Sep 2024